Albany, NY -- (SBWIRE) -- 08/15/2016 -- An implantable cardioverter defibrillator is a device that monitors a person's heart rate post its implantation in patients with heart failure. The device continuously monitors your heartbeat and sends electrical pulses to repair a normal heart rhythm when necessary. Implantable cardioverter defibrillator (ICD) or automated implantable cardioverter defibrillators can save patients from arrhythmias by regulating the irregular heartbeats. The device is used in treating sudden cardiac arrest caused due to cardiac arrhythmias, particularly ventricular fibrillation and pulseless ventricular tachycardia. Invention of the implantable cardioverter defibrillator was started by Michel Mirowski in the late 1960s after one of his close friend's death who was also his mentor and had been admitted to hospital with recurrent ventricular tachyarrhythmias.

Download Free Report Brochure PDF:http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13826

The most important factors driving the global implantable cardioverter defibrillators market are increasing incidences of cardiovascular disorders, increasing demand for implantable cardioverter defibrillator from emerging countries of Asia-Pacific and the Middle-East as cardiovascular disorders are increasing and awareness about the disease also increases in these countries, increasing number of training and awareness programs across the globe for Implantable Cardioverter Defibrillators. These training and awareness programs are conducted for the patients as well as the surgeons by Mayo Clinic US.

The implantable cardioverter defibrillators governs the appropriate therapy for returning your heartbeat to a normal heart rhythm. Doctor programs the implantable cardioverter defibrillators to deliver functions such as anti-tachycardia pacing (ATP) and cardio. A series of small electrical impulses are delivered to the heart muscle to restore a normal heart rate and rhythm. In cardio, a low energy shock is delivered at the same time as your heartbeat to restore a normal heart rhythm. Defibrillation means when the heart is beating dangerously fast, a high-energy shock is delivered to the heart muscle to restore a normal rhythm. Bradycardia pacing means when the heart beats too slow, small electrical impulses are sent to stimulate the heart muscle to maintain a suitable heart rate.

The American Heart Association recommends some guide lines for the person to be eligible for an implantable cardioverter defibrillator. The arrhythmia in question must be life threatening and the correctable causes of arrhythmia (acute myocardial infarction, myocardial ischemia, electrolyte imbalance and drug toxicity) have been ruled out by doctors have ruled out correctable causes of the arrhythmia.

Implantable cardioverter defibrillators market can be segmented by product types, by procedure type, and end user type. Implantable cardioverter defibrillator are categories into single chambered, dual chambered and biventricular implantable cardioverter defibrillators on product types. Based on implantation region ICDs are categorized into trans-venous implantable cardioverter defibrillators and subcutaneous implantable cardioverter defibrillators.The subcutaneous ICD (S-ICD) is placed without inserting the leads inside the heart. The device is placed under the skin below the left axilla, or armpit along the rib cage, and not inserting in the standard location near the collarbone. The lead which is connected to the device is burrowed under the skin rather than inside the heart. The advantages of the S-ICD are that it do not show any of the immediate or long-term complications followed due to placing a lead into the heart, such as perforation of the heart and collapse of the lung. Subcutaneous Implantable Cardioverter Defibrillators is the key driver for the ICD market as it have very less complications and easy implantable procedure. Based on end user type the ICDs are divided into hospital and super specialty hospitals, home users, cardiac catheterization laboratory users and electrophysiology laboratory users. Geographically, the market has been categorized in five main regions: North America, Europe, Latin America, Asia pacific and the Middle East and Africa.

The key implantable cardioverter defibrillators manufacturer companies include Boston Scientific Corporation, Imricor Medical Systems, Inc., LivaNova PLC Company, Mayo Clinic US, Medtronic plc, MicroPort Scientific Corporation, MRI Interventions, Inc., St. Jude Medical, Inc.,

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.

Browse Full Report@ http://www.transparencymarketresearch.com/implantable-cardioverter-defibrillator-market.html

About Transparency Market Research
Transparency Market Research is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact Us:
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com